Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
20.8M
-
Number of holders
-
210
-
Total 13F shares, excl. options
-
175M
-
Shares change
-
+1.4M
-
Total reported value, excl. options
-
$945M
-
Value change
-
-$13.6M
-
Put/Call ratio
-
0.96
-
Number of buys
-
114
-
Number of sells
-
-98
-
Price
-
$5.39
Significant Holders of Nektar Therapeutics - Common Stock, par value $0.0001 per share (NKTR) as of Q1 2022
292 filings reported holding NKTR - Nektar Therapeutics - Common Stock, par value $0.0001 per share as of Q1 2022.
Nektar Therapeutics - Common Stock, par value $0.0001 per share (NKTR) has 210 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 175M shares
.
Largest 10 shareholders include Invesco Ltd. (37.2M shares), BlackRock Inc. (26.1M shares), VANGUARD GROUP INC (19.4M shares), PRIMECAP MANAGEMENT CO/CA/ (17.1M shares), WELLINGTON MANAGEMENT GROUP LLP (11.4M shares), STATE STREET CORP (5.8M shares), Bellevue Group AG (4.81M shares), MAVERICK CAPITAL LTD (4.79M shares), FIRST TRUST ADVISORS LP (4.39M shares), and Camber Capital Management LP (4M shares).
This table shows the top 210 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.